{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:32:16Z","timestamp":1793802736915,"version":"4.6.1"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11904-024-00718-9","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:30:08Z","timestamp":1733963408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Challenges of HIV Management in an Aging Population"],"prefix":"10.1007","volume":"22","author":[{"given":"Ashmitha","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer F.","family":"Hoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"718_CR1","volume-title":"Diagnoses, deaths, and prevalence of HIV in the United States and 6 territories and freely associated states, 2022. HIV Surveillance Report, 2022","author":"Centers for Disease Control and Prevention","year":"2022","unstructured":"Centers for Disease Control and Prevention. Diagnoses, deaths, and prevalence of HIV in the United States and 6 territories and freely associated states, 2022. HIV Surveillance Report, 2022. In: Services. USDoHaH, editor.; 2022."},{"key":"718_CR2","volume-title":"HIV, viral hepatitis and sexually transmissible infections in Australia: Annual surveillance report 2023","author":"J King","year":"2023","unstructured":"King J, McManus H, Kwon A, Gray R, McGregor. S. HIV, viral hepatitis and sexually transmissible infections in Australia: Annual surveillance report 2023. UNSW; 2023. [cited 2024."},{"issue":"3","key":"718_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/QAD.0000000000003128","volume":"36","author":"KN Althoff","year":"2022","unstructured":"Althoff KN, Stewart CN, Humes E, Zhang J, Gerace L, Boyd CM, et al. The shifting age distribution of people with HIV using antiretroviral therapy in the United States. AIDS. 2022;36(3):459\u201371.","journal-title":"AIDS"},{"issue":"5","key":"718_CR4","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3018(23)00028-0","volume":"10","author":"A Trickey","year":"2023","unstructured":"Trickey A, Sabin CA, Burkholder G, Crane H, d\u2019Arminio Monforte A, Egger M, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV. 2023;10(5):e295\u2013307.","journal-title":"Lancet HIV"},{"issue":"4","key":"718_CR5","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/S2352-3018(22)00003-0","volume":"9","author":"AC Justice","year":"2022","unstructured":"Justice AC, Goetz MB, Stewart CN, Hogan BC, Humes E, Luz PM, et al. Delayed presentation of HIV among older individuals: a growing problem. Lancet HIV. 2022;9(4):e269\u201380.","journal-title":"Lancet HIV"},{"issue":"8","key":"718_CR6","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/hiv.13125","volume":"22","author":"A Zhabokritsky","year":"2021","unstructured":"Zhabokritsky A, Szadkowski L, Burchell AN, Cooper C, Hogg RS, Hull M, et al. Immunological and virological response to initial antiretroviral therapy among older people living with HIV in the Canadian Observational Cohort (CANOC). HIV Med. 2021;22(8):759\u201369.","journal-title":"HIV Med"},{"issue":"1","key":"718_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40168-024-01758-4","volume":"12","author":"S Singh","year":"2024","unstructured":"Singh S, Giron LB, Shaikh MW, Shankaran S, Engen PA, Bogin ZR, et al. Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging. Microbiome. 2024;12(1):31.","journal-title":"Microbiome"},{"issue":"11","key":"718_CR8","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1161\/CIRCRESAHA.124.324296","volume":"134","author":"AO Hinton Jr","year":"2024","unstructured":"Hinton AO Jr., N\u2019Jai AU, Vue Z, Wanjalla C. Connection between HIV and mitochondria in cardiovascular disease and implications for treatments. Circul Res. 2024;134(11):1581\u2013606.","journal-title":"Circul Res"},{"issue":"2","key":"718_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/QAD.0000000000002063","volume":"33","author":"D De Francesco","year":"2019","unstructured":"De Francesco D, Wit FW, Burkle A, Oehlke S, Kootstra NA, Winston A, et al. Do people living with HIV experience greater age advancement than their HIV-negative counterparts? AIDS. 2019;33(2):259\u201368.","journal-title":"AIDS"},{"issue":"5","key":"718_CR10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40265-016-0546-7","volume":"76","author":"DC Hsu","year":"2016","unstructured":"Hsu DC, Sereti I. Serious non-AIDS events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection. Drugs. 2016;76(5):533\u201349.","journal-title":"Drugs"},{"issue":"5","key":"718_CR11","doi-asserted-by":"publisher","first-page":"e0155100","DOI":"10.1371\/journal.pone.0155100","volume":"11","author":"B Grund","year":"2016","unstructured":"Grund B, Baker JV, Deeks SG, Wolfson J, Wentworth D, Cozzi-Lepri A, et al. Relevance of Interleukin-6 and D-Dimer for serious Non-AIDS morbidity and death among HIV-Positive adults on suppressive antiretroviral therapy. PLoS ONE [Electronic Resource]. 2016;11(5):e0155100.","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"1","key":"718_CR12","doi-asserted-by":"publisher","first-page":"e1004325","DOI":"10.1371\/journal.pmed.1004325","volume":"21","author":"KN Althoff","year":"2024","unstructured":"Althoff KN, Stewart C, Humes E, Gerace L, Boyd C, Gebo K, et al. The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: a modeling study. PLoS Med. 2024;21(1):e1004325.","journal-title":"PLoS Med"},{"issue":"9","key":"718_CR13","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S2352-3018(15)00113-7","volume":"2","author":"M Cornell","year":"2015","unstructured":"Cornell M, Johnson LF, Schomaker M, Tanser F, Maskew M, Wood R, et al. Age in antiretroviral therapy programmes in South Africa: a retrospective, multicentre, observational cohort study. Lancet HIV. 2015;2(9):e368\u201375.","journal-title":"Lancet HIV"},{"key":"718_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/7854_2019_119","volume":"50","author":"J Falutz","year":"2021","unstructured":"Falutz J, Kirkland S, Guaraldi G. Geriatric syndromes in people living with HIV associated with ageing and increasing comorbidities: implications for neurocognitive complications of HIV infection. Curr Top Behav Neurosci. 2021;50:301\u201327.","journal-title":"Curr Top Behav Neurosci"},{"issue":"1","key":"718_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/hiv.13325","volume":"24","author":"KA Siddiqi","year":"2023","unstructured":"Siddiqi KA, Ostermann J, Zhang J, Khan MM, Olatosi B. Ageing with HIV in the United States: changing trends in inpatient hospital stays and comorbidities, 2003\u20132015. HIV Med. 2023;24(1):93\u2013103.","journal-title":"HIV Med"},{"issue":"12","key":"718_CR16","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/hiv.13592","volume":"24","author":"J Dawe","year":"2023","unstructured":"Dawe J, Cassano D, Keane R, Ruth S, Wilkinson AL, Elsum I, et al. Quality of life among people living with HIV aged 50 years and over in Australia: identifying opportunities to support better ageing. HIV Med. 2023;24(12):1253\u201367.","journal-title":"HIV Med"},{"issue":"1","key":"718_CR17","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2352-3018(23)00226-6","volume":"11","author":"G Guaraldi","year":"2024","unstructured":"Guaraldi G, Milic J, Cascio M, Mussini C, Martinez E, Levin J, et al. Ageism: the -ism affecting the lives of older people living with HIV. Lancet HIV. 2024;11(1):e52\u20139.","journal-title":"Lancet HIV"},{"issue":"5","key":"718_CR18","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/QAI.0000000000001450","volume":"75","author":"DR Drozd","year":"2017","unstructured":"Drozd DR, Kitahata MM, Althoff KN, Zhang J, Gange SJ, Napravnik S, et al. Increased risk of myocardial infarction in HIV-Infected individuals in North America compared with the General Population. J Acquir Immune Defic Syndromes: JAIDS. 2017;75(5):568\u201376.","journal-title":"J Acquir Immune Defic Syndromes: JAIDS"},{"issue":"11","key":"718_CR19","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIRCRESAHA.124.323948","volume":"134","author":"K McCutcheon","year":"2024","unstructured":"McCutcheon K, Nqebelele U, Murray L, Thomas TS, Mpanya D, Tsabedze N. Cardiac and renal comorbidities in aging people living with HIV. Circul Res. 2024;134(11):1636\u201360.","journal-title":"Circul Res"},{"issue":"2","key":"718_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/infdis\/jiu417","volume":"211","author":"M Lichtner","year":"2015","unstructured":"Lichtner M, Cicconi P, Vita S, Cozzi-Lepri A, Galli M, Lo Caputo S, et al. Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. J Infect Dis. 2015;211(2):178\u201386.","journal-title":"J Infect Dis"},{"issue":"4","key":"718_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1089\/aid.2023.0055","volume":"40","author":"L Mavarani","year":"2024","unstructured":"Mavarani L, Reinsch N, Albayrak-Rena S, Potthoff A, Hower M, Dolff S, et al. The association of HIV-specific risk factors with cardiovascular events in addition to traditional risk factors in people living with HIV. AIDS Res Hum Retrovir. 2024;40(4):235\u201345.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"10","key":"718_CR22","doi-asserted-by":"publisher","first-page":"e029228","DOI":"10.1161\/JAHA.123.029228","volume":"13","author":"VA Triant","year":"2024","unstructured":"Triant VA, Lyass A, Hurley LB, Borowsky LH, Ehrbar RQ, He W, et al. Cardiovascular risk estimation is suboptimal in people with HIV. J Am Heart Assoc. 2024;13(10):e029228.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"718_CR23","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/infdis\/jiw342","volume":"214","author":"L Ryom","year":"2016","unstructured":"Ryom L, Lundgren JD, Ross M, Kirk O, Law M, Morlat P, et al. Renal impairment and cardiovascular disease in HIV-positive individuals: the D: A: D study. J Infect Dis. 2016;214(8):1212\u201320.","journal-title":"J Infect Dis"},{"issue":"8","key":"718_CR24","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2304146","volume":"389","author":"SK Grinspoon","year":"2023","unstructured":"Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med. 2023;389(8):687\u201399.","journal-title":"N Engl J Med"},{"issue":"3","key":"718_CR25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/QAD.0000000000003373","volume":"37","author":"N Jaschinski","year":"2023","unstructured":"Jaschinski N, Greenberg L, Neesgaard B, Miro JM, Grabmeier-Pfistershammer K, Wandeler G, et al. Recent abacavir use and incident cardiovascular disease in contemporary-treated people with HIV. AIDS. 2023;37(3):467\u201375.","journal-title":"AIDS"},{"issue":"1","key":"718_CR26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/QAD.0000000000001666","volume":"32","author":"CA Sabin","year":"2018","unstructured":"Sabin CA, Ryom L, d\u2019Arminio Monforte A, Hatleberg CI, Pradier C, El-Sadr W, et al. Abacavir use and risk of recurrent myocardial infarction. AIDS. 2018;32(1):79\u201388.","journal-title":"AIDS"},{"issue":"6","key":"718_CR27","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1016\/S2352-3018(18)30043-2","volume":"5","author":"L Ryom","year":"2018","unstructured":"Ryom L, Lundgren JD, El-Sadr W, Reiss P, Kirk O, Law M, et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV. 2018;5(6):e291\u2013300.","journal-title":"Lancet HIV"},{"issue":"6","key":"718_CR28","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1097\/QAD.0000000000002811","volume":"35","author":"The RESPOND Study Group","year":"2021","unstructured":"The RESPOND Study Group. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. AIDS. 2021;35(6):869\u201382.","journal-title":"AIDS"},{"issue":"6","key":"718_CR29","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciz999","volume":"71","author":"PE Sax","year":"2020","unstructured":"Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379\u201389.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"718_CR30","doi-asserted-by":"publisher","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","volume":"7","author":"WDF Venter","year":"2020","unstructured":"Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020;7(10):e666\u201376.","journal-title":"Lancet HIV"},{"key":"718_CR31","doi-asserted-by":"crossref","unstructured":"Drechsler H, Ayers C, Oboho I, Enwerem N, Hanna J, Clark C et al. Choice of antiretroviral therapy has low impact on weight gain. AIDS. 2024;38(12):1731\u20131739.","DOI":"10.1097\/QAD.0000000000003950"},{"key":"718_CR32","doi-asserted-by":"publisher","first-page":"7652408","DOI":"10.1155\/2022\/7652408","volume":"2022","author":"LA Tucker","year":"2022","unstructured":"Tucker LA, Parker K. 10-year weight gain in 13,802 US adults: the role of age, sex, and race. J Obes. 2022;2022:7652408.","journal-title":"J Obes"},{"key":"718_CR33","first-page":"04","volume":"04","author":"D Anderson","year":"2024","unstructured":"Anderson D, Ramgopal M, Hagins DP, Lee J, Simonson RB, Hsu TH, et al. DEFINE: a prospective, randomized, phase 4 trial to assess a protease inhibitor-based regimen switch Strategy to manage integrase inhibitor-related Weight Gain. Clin Infect Dis. 2024;04:04.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"718_CR34","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/cid\/ciac130","volume":"76","author":"JM Llibre","year":"2023","unstructured":"Llibre JM, Brites C, Cheng CY, Osiyemi O, Galera C, Hocqueloux L, et al. Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with Human Immunodeficiency Virus 1 (HIV-1): Week 48 results from the phase 3, noninferiority SALSA randomized trial. Clin Infect Dis. 2023;76(4):720\u20139.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"718_CR35","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"J van Wyk","year":"2020","unstructured":"van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla Sogorb J, et al. Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020;71(8):1920\u20139.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"718_CR36","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/cid\/ciac949","volume":"76","author":"B Bosch","year":"2023","unstructured":"Bosch B, Akpomiemie G, Chandiwana N, Sokhela S, Hill A, McCann K, et al. Weight and metabolic changes after switching from Tenofovir Alafenamide\/Emtricitabine (FTC)\u2009+\u2009Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)\/FTC\u2009+\u2009DTG, and TDF\/FTC\/Efavirenz to TDF\/Lamivudine\/DTG. Clin Infect Dis. 2023;76(8):1492\u20135.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"718_CR37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/cid\/ciad545","volume":"78","author":"SH Bares","year":"2024","unstructured":"Bares SH, Wu X, Tassiopoulos K, Lake JE, Koletar SL, Kalayjian R, et al. Weight gain after antiretroviral therapy initiation and subsequent risk of metabolic and cardiovascular disease. Clin Infect Dis. 2024;78(2):395\u2013401.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"718_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/COH.0000000000000829","volume":"19","author":"A Hill","year":"2024","unstructured":"Hill A, Venter WDF. Clinical consequences of weight gain during treatment for HIV infection. Curr Opin HIV AIDS. 2024;19(1):21\u20139.","journal-title":"Curr Opin HIV AIDS"},{"issue":"5","key":"718_CR39","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/QAI.0000000000002603","volume":"86","author":"K Petoumenos KPa","year":"2021","unstructured":"Petoumenos KPa K, LMSa R, LMDPb M, APc R, PMDPde, De Wit, SMDf, et al. Effect of changes in body Mass Index on the risk of cardiovascular disease and Diabetes Mellitus in HIV-positive individuals: results from the D: A: D study. JAIDS J Acquir Immune Defic Syndr. 2021;86(5):579\u201386.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"8","key":"718_CR40","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S2213-8587(24)00150-5","volume":"12","author":"AR Eckard","year":"2024","unstructured":"Eckard AR, Wu Q, Sattar A, Ansari-Gilani K, Labbato D, Foster T, et al. Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial. Lancet Diabetes Endocrinol. 2024;12(8):523\u201334.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"718_CR41","first-page":"19","volume":"19","author":"Q Nguyen","year":"2024","unstructured":"Nguyen Q, Wooten D, Lee D, Moreno M, Promer K, Rajagopal A, et al. GLP-1 receptor agonists promote weight loss among people with HIV. Clin Infect Dis. 2024;19:19.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"718_CR42","doi-asserted-by":"publisher","first-page":"e0285787","DOI":"10.1371\/journal.pone.0285787","volume":"18","author":"J Penner","year":"2023","unstructured":"Penner J, Ombajo LA, Otieno D, Nkuranga J, Mburu M, Wahome S, et al. High rates of kidney impairment among older people (>\u2009=\u200960 years) living with HIV on first-line antiretroviral therapy at screening for a clinical trial in Kenya. PLoS ONE [Electronic Resource]. 2023;18(6):e0285787.","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"3","key":"718_CR43","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/ndt\/gfw064","volume":"32","author":"J Milburn","year":"2017","unstructured":"Milburn J, Jones R, Levy JB. Renal effects of novel antiretroviral drugs. Nephrol Dial Transplant. 2017;32(3):434\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"718_CR44","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1097\/QAD.0000000000003831","volume":"38","author":"N Li","year":"2024","unstructured":"Li N, Zheng HY, He WQ, He XY, Li R, Cui WB, et al. Treatment outcomes amongst older people with HIV infection receiving antiretroviral therapy. AIDS. 2024;38(6):803\u201312.","journal-title":"AIDS"},{"issue":"5","key":"718_CR45","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/hiv.13596","volume":"25","author":"DM McGee","year":"2024","unstructured":"McGee DM, Cotter AG. HIV and fracture: risk, assessment and intervention. HIV Med. 2024;25(5):511\u201328.","journal-title":"HIV Med"},{"issue":"6","key":"718_CR46","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1111\/jgs.18304","volume":"71","author":"JA Womack","year":"2023","unstructured":"Womack JA, Murphy TE, Leo-Summers L, Bates J, Jarad S, Gill TM, et al. Assessing the contributions of modifiable risk factors to serious falls and fragility fractures among older persons living with HIV. J Am Geriatr Soc. 2023;71(6):1891\u2013901.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"718_CR47","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1016\/S2352-3018(18)30295-9","volume":"6","author":"KN Althoff","year":"2019","unstructured":"Althoff KN, Gebo KA, Moore RD, Boyd CM, Justice AC, Wong C, et al. Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. Lancet HIV. 2019;6(2):e93\u2013104.","journal-title":"Lancet HIV"},{"issue":"3","key":"718_CR48","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2468-1253(16)30120-0","volume":"2","author":"EC Verna","year":"2017","unstructured":"Verna EC. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV. Lancet Gastroenterol Hepatol. 2017;2(3):211\u201323.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"718_CR49","doi-asserted-by":"publisher","first-page":"ofae266","DOI":"10.1093\/ofid\/ofae266","volume":"11","author":"LE van Eekeren","year":"2024","unstructured":"van Eekeren LE, Vadaq N, Vos W, Blaauw MJT, Groenendijk AL, van Lunzen J, et al. Liver steatosis is prevalent in lean people with HIV and Associated with exposure to antiretroviral treatment-a cross-sectional study. Open Forum Infect. 2024;11(6):ofae266.","journal-title":"Open Forum Infect"},{"issue":"6","key":"718_CR50","doi-asserted-by":"publisher","first-page":"835","DOI":"10.7326\/M23-3354","volume":"177","author":"JE Lake","year":"2024","unstructured":"Lake JE, Kitch DW, Kantor A, Muthupillai R, Klingman KL, Vernon C, et al. The effect of open-label semaglutide on metabolic dysfunction-associated steatotic liver disease in people with HIV. Ann Intern Med. 2024;177(6):835\u20138.","journal-title":"Ann Intern Med"},{"key":"718_CR51","unstructured":"European AIDS Clinical Society. EACS Guidelines Version 12.1; 2024. November 2024. https:\/\/eacs.sanfordguide.com\/."},{"issue":"3","key":"718_CR52","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1093\/brain\/awac465","volume":"146","author":"RK Heaton","year":"2023","unstructured":"Heaton RK, Ellis RJ, Tang B, Marra CM, Rubin LH, Clifford DB, et al. Twelve-year neurocognitive decline in HIV is associated with comorbidities, not age: a CHARTER study. Brain. 2023;146(3):1121\u201331.","journal-title":"Brain"},{"issue":"7","key":"718_CR53","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41582-023-00813-2","volume":"19","author":"S Nightingale","year":"2023","unstructured":"Nightingale S, Ances B, Cinque P, Dravid A, Dreyer AJ, Gisslen M, et al. Cognitive impairment in people living with HIV: consensus recommendations for a new approach. Nat Rev Neurol. 2023;19(7):424\u201333.","journal-title":"Nat Rev Neurol"},{"issue":"Suppl 2","key":"718_CR54","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.1097\/QAD.0000000000001402","volume":"31","author":"S Nightingale","year":"2017","unstructured":"Nightingale S, Winston A. Measuring and managing cognitive impairment in HIV. AIDS. 2017;31(Suppl 2):S165\u201372.","journal-title":"AIDS"},{"issue":"1","key":"718_CR55","doi-asserted-by":"publisher","first-page":"4","DOI":"10.24875\/AIDSRev.19000023","volume":"21","author":"C Hoffmann","year":"2019","unstructured":"Hoffmann C, Llibre JM. Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors. AIDS Rev. 2019;21(1):4\u201310.","journal-title":"AIDS Rev"},{"issue":"1","key":"718_CR56","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/09540121.2019.1622645","volume":"32","author":"P Qin","year":"2020","unstructured":"Qin P, He J, Wang Z, Chen X, Li J, Fung AWT, et al. Efavirenz use and neurocognitive performance among older people living with HIV who were on antiretroviral therapy. AIDS Care. 2020;32(1):12\u201320.","journal-title":"AIDS Care"},{"issue":"6","key":"718_CR57","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.4269\/ajtmh.22-0234","volume":"107","author":"L Boonyagars","year":"2022","unstructured":"Boonyagars L, Kiatsoongsong N, Winitprichagul S. HIV-associated dementia: Associated factors and characteristics of cognitive domain abnormalities in elderly people living with HIV treated with highly active antiretroviral therapy. Am J Trop Med Hygiene. 2022;107(6):1250\u20137.","journal-title":"Am J Trop Med Hygiene"},{"issue":"8","key":"718_CR58","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/cid\/ciab655","volume":"74","author":"RJ Ellis","year":"2022","unstructured":"Ellis RJ, Paolillo E, Saloner R, Heaton RK. Higher comorbidity burden predicts worsening neurocognitive trajectories in people with human immunodeficiency virus. Clin Infect Dis. 2022;74(8):1323\u20138.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"718_CR59","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/v14061151","volume":"14","author":"A Arentoft","year":"2022","unstructured":"Arentoft A, Troxell K, Alvarez K, Aghvinian M, Rivera Mindt M, Cherner M, et al. HIV antiretroviral medication neuropenetrance and neurocognitive outcomes in HIV\u2009+\u2009adults: a review of the literature examining the central nervous system penetration effectiveness score. Viruses. 2022;14(6):26.","journal-title":"Viruses"},{"issue":"13","key":"718_CR60","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1097\/QAD.0000000000003650","volume":"37","author":"CM Shikuma","year":"2023","unstructured":"Shikuma CM, Wojna V, De Gruttola V, Siriwardhana C, Souza SA, Rodriguez-Benitez RJ, et al. Impact of antiretroviral therapy intensification with C-C motif chemokine receptor 5 antagonist maraviroc on HIV-associated neurocognitive impairment. AIDS. 2023;37(13):1987\u201395.","journal-title":"AIDS"},{"issue":"6","key":"718_CR61","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1093\/cid\/ciad265","volume":"77","author":"SL Letendre","year":"2023","unstructured":"Letendre SL, Chen H, McKhann A, Roa J, Vecchio A, Daar ES, et al. Antiretroviral therapy intensification for neurocognitive impairment in human immunodeficiency virus. Clin Infect Dis. 2023;77(6):866\u201374.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"718_CR62","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/jnci\/djr076","volume":"103","author":"MS Shiels","year":"2011","unstructured":"Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103(9):753\u201362.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"718_CR63","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1002\/ijc.34850","volume":"154","author":"EA Stier","year":"2024","unstructured":"Stier EA, Clarke MA, Deshmukh AA, Wentzensen N, Liu Y, Poynten IM, et al. International Anal Neoplasia Society\u2019s consensus guidelines for anal cancer screening. Int J Cancer. 2024;154(10):1694\u2013702.","journal-title":"Int J Cancer"},{"issue":"5","key":"718_CR64","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/QAI.0000000000003452","volume":"96","author":"IA Nicolau","year":"2024","unstructured":"Nicolau IA, Moineddin R, Brooks JD, Antoniou T, Gillis JL, Kendall CE, et al. Associations of CD4 cell count measures with infection-related and infection-unrelated cancer risk among people with HIV. J Acquir Immune Defic Syndromes: JAIDS. 2024;96(5):447\u201356.","journal-title":"J Acquir Immune Defic Syndromes: JAIDS"},{"issue":"3","key":"718_CR65","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/QAI.0000000000003350","volume":"95","author":"BL Dickey","year":"2024","unstructured":"Dickey BL, Yanik EL, Thompson Z, Burkholder G, Kitahata MM, Moore RD, et al. The association of HIV control and immunosuppression with risk of non-AIDS-defining cancer risk among patients on antiretroviral therapy. J Acquir Immune Defic Syndromes: JAIDS. 2024;95(3):275\u201382.","journal-title":"J Acquir Immune Defic Syndromes: JAIDS"},{"issue":"6","key":"718_CR66","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/jnci\/djac053","volume":"114","author":"JL Castilho","year":"2022","unstructured":"Castilho JL, Bian A, Jenkins CA, Shepherd BE, Sigel K, Gill MJ, et al. CD4\/CD8 ratio and cancer risk among adults with HIV. J Natl Cancer Inst. 2022;114(6):854\u201362.","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 2","key":"718_CR67","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1097\/QAD.0000000000001449","volume":"31","author":"A Dalla Pria","year":"2017","unstructured":"Dalla Pria A, Merchant S, Bower M. Oncological challenges for an ageing population living with HIV. AIDS. 2017;31(Suppl 2):S185\u20139.","journal-title":"AIDS"},{"issue":"9","key":"718_CR68","doi-asserted-by":"publisher","first-page":"e191742","DOI":"10.1001\/jamaoncol.2019.1742","volume":"5","author":"AE Coghill","year":"2019","unstructured":"Coghill AE, Suneja G, Rositch AF, Shiels MS, Engels EA. HIV infection, cancer treatment regimens, and cancer outcomes among elderly adults in the United States. JAMA Oncol. 2019;5(9):e191742\u2013e.","journal-title":"JAMA Oncol"},{"issue":"4","key":"718_CR69","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1016\/S2666-7568(21)00033-7","volume":"2","author":"SO Verboeket","year":"2021","unstructured":"Verboeket SO, Boyd A, Wit FW, Verheij E, van der Schim MF, Kootstra N, et al. Changes in lung function among treated HIV-positive and HIV-negative individuals: analysis of the prospective AGE\u2009<\u2009sub\u2009>\u2009h\u2009IV cohort study. Lancet Healthy Longev. 2021;2(4):e202\u201311.","journal-title":"Lancet Healthy Longev"},{"issue":"1","key":"718_CR70","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/cid\/ciz728","volume":"71","author":"HM Garcia Garrido","year":"2020","unstructured":"Garcia Garrido HM, Mak AMR, Wit F, Wong GWM, Knol MJ, Vollaard A, et al. Incidence and risk factors for Invasive pneumococcal disease and community-acquired pneumonia in human immunodeficiency virus-infected individuals in a high-income setting. Clin Infect Dis. 2020;71(1):41\u201350.","journal-title":"Clin Infect Dis"},{"key":"718_CR71","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.2147\/COPD.S388142","volume":"18","author":"KL Byanova","year":"2023","unstructured":"Byanova KL, Abelman R, North CM, Christenson SA, Huang L. COPD in people with HIV: Epidemiology, pathogenesis, management, and prevention strategies. Int J Copd. 2023;18:2795\u2013817.","journal-title":"Int J Copd"},{"issue":"10","key":"718_CR72","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1097\/TP.0000000000003107","volume":"104","author":"I Campos-Varela","year":"2020","unstructured":"Campos-Varela I, Dodge JL, Berenguer M, Adam R, Samuel D, Di Benedetto F, et al. Temporal trends and outcomes in liver transplantation for recipients with HIV infection in Europe and United States. Transplantation. 2020;104(10):2078\u201386.","journal-title":"Transplantation"},{"issue":"7","key":"718_CR73","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1097\/TP.0000000000003485","volume":"105","author":"E Muller","year":"2021","unstructured":"Muller E, Botha FCJ, Barday ZA, Manning K, Chin-Hong P, Stock P. Kidney transplantation in HIV-positive patients: current practice and management strategies. Transplantation. 2021;105(7):1492\u2013501.","journal-title":"Transplantation"},{"issue":"1","key":"718_CR74","doi-asserted-by":"publisher","first-page":"e13440","DOI":"10.1111\/ctr.13440","volume":"33","author":"C Chen","year":"2019","unstructured":"Chen C, Wen X, Yadav A, Belviso N, Kogut S, McCauley J. Outcomes in human immunodeficiency virus-infected recipients of heart transplants. Clin Transplant. 2019;33(1):e13440.","journal-title":"Clin Transplant"},{"issue":"9","key":"718_CR75","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1111\/ajt.16569","volume":"21","author":"I Campos-Varela","year":"2021","unstructured":"Campos-Varela I, Dodge JL, Terrault NA, Brandman D, Price JC. Nonviral liver disease is the leading indication for liver transplant in the United States in persons living with human immunodeficiency virus. Am J Transplant. 2021;21(9):3148\u201356.","journal-title":"Am J Transplant"},{"issue":"11","key":"718_CR76","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1097\/QAD.0000000000003973","volume":"38","author":"EM King","year":"2024","unstructured":"King EM, Tkachuk S, Tseng A. Aging on antiretrovirals: reviewing the need for pharmacologic data in elderly people with HIV. AIDS. 2024;38(11):1609\u201316.","journal-title":"AIDS"},{"issue":"2","key":"718_CR77","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/COH.0000000000000614","volume":"15","author":"A Richterman","year":"2020","unstructured":"Richterman A, Sax PE. Antiretroviral therapy in older people with HIV. Curr Opin HIV AIDS. 2020;15(2):118\u201325.","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"718_CR78","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2022.22246","volume":"329","author":"RT Gandhi","year":"2023","unstructured":"Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA panel. JAMA. 2023;329(1):63\u201384.","journal-title":"JAMA"},{"key":"718_CR79","unstructured":"Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV; 2024. 9th August 2024. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv."},{"key":"718_CR80","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12916-016-0588-4","volume":"14","author":"CA Sabin","year":"2016","unstructured":"Sabin CA, Reiss P, Ryom L, Phillips AN, Weber R, Law M, et al. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Med. 2016;14:61.","journal-title":"BMC Med"},{"issue":"9","key":"718_CR81","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1097\/QAD.0000000000002223","volume":"33","author":"SK Gupta","year":"2019","unstructured":"Gupta SK, Post FA, Arribas JR, Eron JJ Jr., Wohl DA, Clarke AE, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019;33(9):1455\u201365.","journal-title":"AIDS"},{"issue":"10","key":"718_CR82","doi-asserted-by":"publisher","first-page":"e655","DOI":"10.1016\/S2352-3018(19)30195-X","volume":"6","author":"F Maggiolo","year":"2019","unstructured":"Maggiolo F, Rizzardini G, Raffi F, Pulido F, Mateo-Garcia MG, Molina JM, et al. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial. Lancet HIV. 2019;6(10):e655\u201366.","journal-title":"Lancet HIV"},{"issue":"8","key":"718_CR83","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/v15081740","volume":"15","author":"M Mazzitelli","year":"2023","unstructured":"Mazzitelli M, Sasset L, Gardin S, Leoni D, Trunfio M, Scaglione V, et al. Real-life experience on dolutegravir and lamivudine as initial or switch therapy in a silver population living with HIV. Viruses. 2023;15(8):15.","journal-title":"Viruses"},{"issue":"2","key":"718_CR84","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1089\/aid.2023.0046","volume":"40","author":"L Calza","year":"2024","unstructured":"Calza L, Colangeli V, Legnani G, Cretella S, Bon I, Viale P. Efficacy and safety of switching to dolutegravir\/lamivudine in virologically suppressed people living with HIV-1 aged over 65 years. AIDS Res Hum Retrovir. 2024;40(2):73\u20139.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"1","key":"718_CR85","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/hiv.13319","volume":"24","author":"F Maggiolo","year":"2023","unstructured":"Maggiolo F, Rizzardini G, Molina JM, Pulido F, De Wit S, Vandekerckhove L, et al. Bictegravir\/emtricitabine\/tenofovir alafenamide in older individuals with HIV: results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people\u2009>\u2009=\u200965 years of age. HIV Med. 2023;24(1):27\u201336.","journal-title":"HIV Med"},{"issue":"38","key":"718_CR86","doi-asserted-by":"publisher","first-page":"e27330","DOI":"10.1097\/MD.0000000000027330","volume":"100","author":"CP Rolle","year":"2021","unstructured":"Rolle CP, Nguyen V, Patel K, Cruz D, DeJesus E, Hinestrosa F. Real-world efficacy and safety of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in older people living with HIV. Medicine. 2021;100(38):e27330.","journal-title":"Medicine"},{"key":"718_CR87","unstructured":"Elliot ER, D\u2019Amico R, Clark A, Polli JW, Garside L, Roberts J et al. Long-acting cabotegravir\u2009+\u2009rilpivirine in older adults: Pooled phase 3 week 96 results. 24th International AIDS Conference; July 29-August 2, 2022; Montreal, Canada; 2022."},{"issue":"Suppl 1","key":"718_CR88","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/ggi.14717","volume":"24","author":"C Yang","year":"2024","unstructured":"Yang C, Teh YE, Chua NGS, Lee KLS, Ng RQM. An overview of multimorbidity and polypharmacy in older people living with HIV. Geriatr Gerontol Int. 2024;24(Suppl 1):49\u201359.","journal-title":"Geriatr Gerontol Int"},{"issue":"2","key":"718_CR89","doi-asserted-by":"publisher","first-page":"e25449","DOI":"10.1002\/jia2.25449","volume":"23","author":"D Back","year":"2020","unstructured":"Back D, Marzolini C. The challenge of HIV treatment in an era of polypharmacy. J Int AIDS Soc. 2020;23(2):e25449.","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"718_CR90","first-page":"419","volume":"29","author":"VC Mandyam","year":"2022","unstructured":"Mandyam VC, Bruce RD. Chronic pain and opioid use in older people with HIV. Top Antiviral Med. 2022;29(5):419\u201322.","journal-title":"Top Antiviral Med"},{"issue":"12","key":"718_CR91","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/hiv.13532","volume":"24","author":"J Doctor","year":"2023","unstructured":"Doctor J, Winston A, Vera JH, Post FA, Boffito M, Mallon PWG, et al. Anticholinergic medications associated with falls and frailty in people with HIV. HIV Med. 2023;24(12):1198\u2013209.","journal-title":"HIV Med"},{"issue":"12","key":"718_CR92","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/17512433.2017.1377610","volume":"10","author":"A Chary","year":"2017","unstructured":"Chary A, Nguyen NN, Maiton K, Holodniy M. A review of drug-drug interactions in older HIV-infected patients. Expert Rev Clin Pharmacol. 2017;10(12):1329\u201352.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"718_CR93","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/17512433.2019.1627200","volume":"12","author":"C Marzolini","year":"2019","unstructured":"Marzolini C, Livio F. Prescribing issues in elderly individuals living with HIV. Expert Rev Clin Pharmacol. 2019;12(7):643\u201359.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"718_CR94","doi-asserted-by":"publisher","first-page":"ofac129","DOI":"10.1093\/ofid\/ofac129","volume":"9","author":"Y Yamada","year":"2022","unstructured":"Yamada Y, Kobayashi T, Condo A, Sangarlangkarn A, Ko F, Taniguchi Y, et al. Prevalence of frailty and prefrailty in people with human immunodeficiency virus aged 50 or older: a systematic review and Meta-analysis. Open Forum Infect. 2022;9(5):ofac129.","journal-title":"Open Forum Infect"},{"issue":"2","key":"718_CR95","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3851\/IMP3185","volume":"23","author":"HL Yeoh","year":"2018","unstructured":"Yeoh HL, Cheng A, Palmer C, Crowe SM, Hoy JF. Frailty in men living with HIV: a cross-sectional comparison of three frailty instruments. Antivir Ther. 2018;23(2):117\u201327.","journal-title":"Antivir Ther"},{"issue":"2","key":"718_CR96","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/hiv.12988","volume":"22","author":"A Beanland","year":"2021","unstructured":"Beanland A, Alagaratnam J, Goffe C, Bailey A, Dosekun O, Petersen C, et al. Objective and subjective rapid frailty screening tools in people with HIV. HIV Med. 2021;22(2):146\u201350.","journal-title":"HIV Med"},{"issue":"5","key":"718_CR97","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/COH.0000000000000305","volume":"11","author":"KN Althoff","year":"2016","unstructured":"Althoff KN, Smit M, Reiss P, Justice AC. HIV and ageing: improving quantity and quality of life. Curr Opin HIV AIDS. 2016;11(5):527\u201336.","journal-title":"Curr Opin HIV AIDS"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-024-00718-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-024-00718-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-024-00718-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:05:18Z","timestamp":1769605518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-024-00718-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["718"],"URL":"https:\/\/doi.org\/10.1007\/s11904-024-00718-9","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"assertion":[{"value":"2 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"JH\u2019s institution received reimbursement for her time on Advisory Boards for Gilead Sciences and ViiV Healthcare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8"}}